INTRODUCTION {#s1}
============

Monoclonal gammopathy of undetermined significance (MGUS) is a precursor lesion to overt multiple myeloma (MM), a clonal B-cell malignancy characterized by excessive multiplication of a plasma cell clone(s) in bone marrow, and accumulation of either a monoclonal immunoglobulin (Ig) (M-protein) or an Ig-free light chain in blood \[[@R1]\]. During the last decade, MM treatment and patient outcomes improved remarkably after the introduction of novel agents and autologous stem cell transplantation (ASCT) \[[@R2]\]. However, even with the best combination of currently available drugs, a cure is not achieved for most MM patients \[[@R2], [@R3]\]. Better characterization of neoplastic cells and microenvironment in particular myeloma stages is therefore needed as well as clarifying of reason(s) for treatment failure in most MM patients \[[@R2], [@R3], [@R4]\]. The neoplastic plasma cells in MGUS and MM share similar genetic abnormalities, probably occurring as early events \[[@R5], [@R6]\]. The key role in microenvironment play bone marrow stromal cells and other microenvironmental cells that secrete a plethora of cytokines and growth factors after paracrine stimulation and/or direct interaction with neoplastic cells \[[@R7]\]. Moreover, also myeloma cells secrete numerous cytokines and growth factors \[[@R8], [@R9]\]. The secreted molecules may, in turn, promote homing, migration, proliferation, survival of malignant plasma cells as well as contribute to the bone resorption and drug resistance \[[@R10]\].

Given the key role of cytokines and growth factors in MM pathogenesis, we investigated the complexity of serum microenvironment using novel multiplex highly-sensitive PEA immunoassay on 92 cancer-related proteins followed by pattern-recognition analyses. Besides identification of serum fingerprints distinguishing MGUS and MM, we for the first time compared paired MM samples from the time of diagnosis and after autologous stem cell transplantation (MM-ASCT) as well as MGUS to healthy subjects.

RESULTS {#s2}
=======

Serum protein fingerprinting in MGUS and MM by PEA immunoassay {#s2_1}
--------------------------------------------------------------

To assess the serum protein fingerprints associated with MGUS and MM, we compared serum protein pattern obtained by PEA immunoassay in MGUS and MM and healthy controls. Of ninety-two analyzed biomarkers ([Supplementary Table S1](#SD2){ref-type="supplementary-material"}), levels of six biomarkers (sBTC, CA242, sER, GM-CSF, IL2, IL4) were below the Proseek limit of detection (LOD) in all studied groups and were therefore excluded from further analysis. Comparing MGUS and MM, 26 analytes were deregulated between these groups, whereas 13 analytes reached the significance after the adjustment for multiple comparisons ([Supplementary Table S2A](#SD3){ref-type="supplementary-material"}). The distribution of serum levels of top-ranked proteins (ADM, TRAP, GDF15, suPAR, REG4, TGFB1, sMICA, IL1RA, HE4, sHGFR, sVEGFA; see Table [1A](#T1){ref-type="table"}), all found upregulated in MM, is shown in Figure [1](#F1){ref-type="fig"}. The protein serum fingerprints associated with MGUS and MM and the changes in protein levels between MGUS and MM for top-deregulated analytes are shown in Figure [2A](#F2){ref-type="fig"}.

###### Serum levels of top-ranked proteins differentiating between A) MGUS *vs* MM, B) healthy controls *vs* MGUS, C) healthy controls *vs* MM, D) MM *vs* MM-ASCT and E) healthy controls *vs* MM-ASCT.

  Analyte    Mean Linear ddCq (95% CI)   FC                  *P*    *P*~*corr*~    
  ---------- --------------------------- ------------------- ------ -------------- --------------
  **A**      *MGUS*                      *MM*                                      
  ADM        46.9 (28.4-65.4)            191 (121-262)       2.80   4.0 × 10^-6^   3.5 × 10^-4^
  TRAP       28.9 (22.3-35.6)            85.1 (42.8-127)     2.33   3.7 × 10^-5^   1.6 × 10^-3^
  GDF15      12.6 (9.19-16.0)            53.3 (22.5-84.1)    2.72   1.1 × 10^-4^   3.0 × 10^-3^
  suPAR      295 (251-338)               486 (368-603)       1.60   2.7 × 10^-4^   5.9 × 10^-3^
  REG4       5.96 (5.46-6.46)            9.58 (6.78-12.4)    1.30   1.2 × 10^-3^   .021
  TGFB1      42.9 (39.0-46.8)            85.5 (43.7-127)     1.41   1.9 × 10^-3^   .023
  sMICA      15.4 (9.98-20.8)            39.4 (26.8-52.1)    2.29   2.1 × 10^-3^   .023
  IL1RA      9.22 (7.23-11.2)            60.0 (0-145)        1.71   2.6 × 10^-3^   .023
  HE4        18.4 (15.6-21.3)            89.8 (0-190)        1.72   3.0 × 10^-3^   .023
  sHGFR      259 (240-278)               580 (199-960)       1.26   3.0 × 10^-3^   .023
  sVEGFA     892 (728-1056)              1628 (1082-2173)    1.47   3.0 × 10^-3^   .023
  **B**      *healthy controls*          *MGUS*                                    
  Midkine    30.3 (25.8-34.8)            75.0 (60.8-89.3)    2.24   8.2 × 10^-6^   7.0 × 10^-4^
  THPO       13.1 (11.7-14.6)            24.2 (18.8-29.6)    1.79   9.8 × 10^-5^   4.2 × 10^-3^
  sTNFRSF4   4.12 (3.29-4.94)            7.39 (6.05-8.72)    1.54   1.6 × 10^-4^   4.4 × 10^-3^
  sHER4      174 (163-184)               270 (228-311)       1.45   2.4 × 10^-4^   4.5 × 10^-3^
  IFNγ       1.58 (1.52-1.64)            2.17 (1.95-2.39)    1.31   3.1 × 10^-4^   4.5 × 10^-3^
  TGFB1      61.9 (54.2-69.5)            42.9 (39.0-46.8)    .71    3.7 × 10^-4^   4.5 × 10^-3^
  sPECAM1    15.6 (12.6-18.7)            28.7 (23.3-34.1)    1.56   3.7 × 10^-4^   4.5 × 10^-3^
  sIL17RB    5.56 (3.84-7.28)            10.9 (9.09-12.7)    1.81   1.1 × 10^-3^   .010
  KLK6       28.6 (24.5-32.8)            44.0 (37.9-50.2)    1.29   1.1 × 10^-3^   .010
  suPAR      425 (373-476)               295 (251-338)       .69    2.0 × 10^-3^   .017
  **C**      *healthy controls*          *MM*                                      
  PGF        59.2 (52.5-66.0)            137 (97.2-177)      1.72   1.6 × 10^-5^   1.4 × 10^-3^
  GDF15      8.34 (6.14-10.5)            53.3 (22.5-84.1)    3.69   9.8 × 10^-5^   4.2 × 10^-3^
  HE4        12.9 (10.4-15.5)            89.8 (0-190)        2.56   1.6 × 10^-4^   4.4 × 10^-3^
  sTNFR2     9.52 (7.93-11.1)            17.9 (14.3-21.6)    1.88   2.4 × 10^-4^   5.3 × 10^-3^
  CSF1       100 (94.4-106)              195 (115-275)       1.64   3.7 × 10^-4^   5.3 × 10^-3^
  Midkine    30.3 (25.8-34.8)            158 (82.9-232)      3.42   3.7 × 10^-4^   5.3 × 10^-3^
  sPECAM1    15.6 (12.6-18.7)            69.6 (17.4-122)     2.38   7.7 × 10^-4^   9.3 × 10^-3^
  CCL19      463 (317-609)               929 (733-1125)      1.76   1.1 × 10^-3^   9.3 × 10^-3^
  sVEGFA     765 (700-830)               1628 (1082-2173)    1.57   1.1 × 10^-3^   9.3 × 10^-3^
  IFNγ       1.58 (1.52-1.64)            5.17 (0-11.1)       1.47   1.1 × 10^-3^   9.3 × 10^-3^
  **D**      *MM*                        *MM-ASCT*                                 
  REG4       9.58 (6.78-12.4)            7.01 (4.50-9.51)    .74    3.1 × 10^-5^   2.6 × 10^-3^
  sBAFF      18.4 (10.5-26.3)            62.3 (51.8-72.9)    4.38   1.5 × 10^-4^   6.1 × 10^-3^
  sPECAM1    69.6 (17.4-122)             17.3 (13.1-21.6)    .41    2.1 × 10^-4^   6.1 × 10^-3^
  sIL6R      174 (99.3-249)              81.6 (64.6-98.6)    .55    5.8 × 10^-4^   .012
  sPDGFB     544 (299-789)               274 (222-327)       .56    7.6 × 10^-4^   .013
  Midkine    158 (82.9-232)              54.5 (42.7-66.3)    .54    1.0 × 10^-3^   .014
  sHGF       47.1 (32.5-61.6)            26.9 (20.7-33.1)    .63    1.3 × 10^-3^   .014
  TGFB1      85.5 (43.7-127)             41.6 (34.9-48.3)    .72    1.3 × 10^-3^   .014
  sAREG      19.0 (5.32-32.8)            7.52 (6.17-8.87)    .67    1.7 × 10^-3^   .016
  sMICA      39.4 (26.8-52.1)            22.5 (15.8-29.2)    .59    2.1 × 10^-3^   .018
  **E**      *healthy controls*          *MM-ASCT*                                 
  sBAFF      14.1 (12.9-15.3)            62.3 (51.8-72.9)    4.32   8.2 × 10^-6^   7.0 × 10^-4^
  CSF1       100 (94.4-106)              152 (131-173)       1.44   2.4 × 10^-4^   6.0 × 10^-3^
  sTGFA      24.4 (19.6-29.2)            11.9 (9.03-14.8)    .36    2.4 × 10^-4^   6.0 × 10^-3^
  TRAP       32.2 (25.0-39.4)            71.2 (42.5-100.0)   1.82   3.7 × 10^-4^   6.0 × 10^-3^
  CXCL10     130 (61.2-199)              667 (323-1011)      4.05   5.4 × 10^-4^   6.0 × 10^-3^
  sTNFR2     9.52 (7.93-11.1)            21.2 (17.6-24.9)    2.45   5.4 × 10^-4^   6.0 × 10^-3^
  sTNFRSF4   4.12 (3.29-4.94)            10.9 (7.21-14.6)    2.22   5.4 × 10^-4^   6.0 × 10^-3^
  Flt3L      254 (225-284)               522 (411-633)       2.07   7.7 × 10^-4^   6.0 × 10^-3^
  GDF15      8.34 (6.14-10.5)            22.7 (16.5-28.8)    2.50   7.7 × 10^-4^   6.0 × 10^-3^
  HE4        12.9 (10.4-15.5)            43.6 (3.61-83.5)    1.88   7.7 × 10^-4^   6.0 × 10^-3^
  THPO       13.1 (11.7-14.6)            28.5 (21.7-35.3)    2.23   7.7 × 10^-4^   6.0 × 10^-3^

FC (Fold Change) between group medians of linear ddCq

\**P*~*corr*~ value corrected for multiple comparisons (Benjamini-Hochberg correction)

![Distribution of serum levels of top-ranked proteins in patients with MGUS *vs* MM\
Group means are indicated by horizontal bars, error bars indicate 95%CI; *P*~*corr*~ values for differences between two groups of patients after multiple corrections are stated.](oncotarget-08-69408-g001){#F1}

###### Serum fingerprints and changes in top-deregulated proteins in MGUS, MM, and MM-ASCT

Fingerprints were presented as FC (fold-change of group medians) of serum levels of deregulated serum proteins between particular groups (*P*\< .05); changes in top-deregulated proteins are presented as percentage of changes between group medians of particular groups: **A**. MGUS *vs* MM, **B**. controls *vs* MGUS, **C**. controls *vs* MM. **D**. MM *vs* MM-ASCT and **E.** controls *vs* MM-ASCT. MGUS is colored yellow, MM red, MM-ASCT blue, and control subjects green.
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Comparison of protein pattern obtained in MGUS and healthy controls revealed deregulation of 33 proteins (Figure [2B](#F2){ref-type="fig"}), of these 21 reached significance after multiple comparisons ([Supplementary Table S2B](#SD3){ref-type="supplementary-material"}). The protein levels of top-ranked proteins (midkine, THPO, sTNFRSF4, sHER4, INFγ, TGFB1, sPECAM1, sIL17RB, KLK6, suPAR) are presented in Table [1B](#T1){ref-type="table"} and [Supplementary Figure S1A](#SD1){ref-type="supplementary-material"}.

When comparing MM and controls, we observed deregulation of 46 serum proteins (Figure [2C](#F2){ref-type="fig"}), of these 41 analytes reached significance after adjustment for multiple comparisons ([Supplementary Table S2C](#SD3){ref-type="supplementary-material"}). The distribution of serum levels of top-ranked proteins between MM and controls (PGF, GDF15, HE4, sTNFR2, CSF1, midkine, sPECAM1, CCL19, sVEGFA, INFγ; see Table [1C](#T1){ref-type="table"}) is shown in [Supplementary Figure S1B](#SD1){ref-type="supplementary-material"}. The subanalysis based on cytogenetic/FISH analysis was not performed due to the high heterogeneity within the group.

Changes in serum protein pattern in post-transplant MM {#s2_2}
------------------------------------------------------

To assess the changes in serum protein pattern in MM after ASCT, we compared the post-transplant sera (day 100) with paired samples obtained in MM patients at the time of diagnosis and healthy control subjects. Comparing paired samples from MM-ASCT and MM, the most upregulated protein in post-transplant sera was sBAFF (*P*~*corr*~= .006), followed by CXCL9 (*P*~*corr*~= .041). Next twenty-one proteins were downregulated (14 proteins after adjustment for multiple comparisons) in MM-ASCT comparing to MM (Figure [2D](#F2){ref-type="fig"}, [Supplementary Table S2D](#SD3){ref-type="supplementary-material"}). The top-ranked proteins were: elevated sBAFF and downregulated REG4, sPECAM1, sIL6R, sPDGFB, midkine, sHGF, TGFB1, sAREG, and sMICA in MM-ASCT comparing to MM (Table [1D](#T1){ref-type="table"}, Figure [3](#F3){ref-type="fig"}). Importantly, serum levels of MM-associated pro-tumorigenic factors such as GDF15, CSF1, suPAR, and HE4 did not change after ASCT comparing to sample at the diagnosis ([Supplementary Table S2D](#SD3){ref-type="supplementary-material"}).

![Changes in serum protein levels between paired samples from MM at the diagnosis and after ASCT (day 100)\
*P*~*corr*~ values for differences between two groups of patients after multiple corrections are stated.](oncotarget-08-69408-g003){#F3}

To exclude the influence of treatment regime on serum pattern, we assessed the protein profile in subgroups based on ASCT induction regime (IMiD-based/bortezomib-based). We did not detect any differences in the cytokine levels as a function of the induction regime as well as the hematological response (CR, VGPR/PR) on day 100 (*P*~*corr*~\> .05).

Comparing to healthy subjects, the serum of post-transplant MM patients showed permanently altered pro-tumorigenic signature characteristic by deregulation of 35 proteins (after multiple adjustments: 28 analytes) (Figure [2E](#F2){ref-type="fig"}, [Supplementary Table S2E](#SD3){ref-type="supplementary-material"}). Except sTGFA and TGFB1, all deregulated proteins were elevated in MM-ASCT. The top-ranked proteins between MM-ASCT and healthy controls were as follows: sBAFF, CSF1, sTGFA, TRAP, CXCL10, sTNFR2, sTNFRSF4, Flt3L, GDF15, HE4, THPO (Table [1E](#T1){ref-type="table"}, [Supplementary Figure S1C](#SD1){ref-type="supplementary-material"}). The serum protein pattern in MM-ASCT and its comparison to those of healthy controls, MGUS and MM, are presented in Figure [4](#F4){ref-type="fig"}.

![Comparison of protein fingerprints in MGUS, MM, MM-ASCT and healthy subjects for selection of top-deregulated proteins](oncotarget-08-69408-g004){#F4}

Pattern-recognition algorithms {#s2_3}
------------------------------

To facilitate the selection of the most promising circulating proteins distinguishing studied groups (MGUS, MM, MM-ASCT, healthy subjects), we applied advanced binary classification algorithm and analyzed co-occurrence of analytes in classification models. The most accurate classification model for separation of MGUS and MM utilized in classification rules most frequently sMICA in combination with other analytes (Figure [5A](#F5){ref-type="fig"}). In MGUS *vs* healthy controls, the classification rules used most often TGFB1 and midkine (Figure [5B](#F5){ref-type="fig"}) and in MM *vs* healthy controls most often sMICA, CXCL11, and midkine (Figure [5C](#F5){ref-type="fig"}). The classification model for MM and MM-ASCT used in the classification rules most frequently sBAFF and CCL21 (Figure [5D](#F5){ref-type="fig"}) and for MM-ASCT and controls used sTGFA and sBAFF (Figure [5E](#F5){ref-type="fig"}).

![Network visualization of classification models obtained by pattern-recognition analysis that identified key serum biomarkers distinguishing between MGUS, MM, and MM-ASCT based on co-occurrence of analytes in classification models\
**A.** MGUS *vs* MM, **B.** controls *vs* MGUS, **C.** controls *vs* MM, **D.** MM *vs* MM-ASCT and **E.** controls *vs* MM-ASCT. The size of the vertices (font-size) and connections among vertices show those proteins, which were used in classification rules of the particular patient group in the most accurate classification model.](oncotarget-08-69408-g005){#F5}

Classification of MGUS, MM, and MM-ASCT {#s2_4}
---------------------------------------

To detect the minimum number and the best combination of serum analytes able to discriminate between MGUS and MM, and MM-ASCT, we applied Multilinear Discriminant Analysis, Naive Bayes classifiers, Random Forests, and extended Support Vector Machine (kSVM). The probability of correct classification to particular patient subgroup (intervals: \>90, 90-80, 80-70, 70-60, and 60-50%) was calculated for every combination of two or three analytes from individual patients, and the misclassification error was determined. The best visual separation of studied patient groups was achieved by kSVM and therefore used in further study. The best dual-combination able to discriminate MGUS *vs* MM was achieved by the combination of sMICA and suPAR, able to separate these groups with a classification error of 0.062 (1 false/16 samples) (Figure [6A](#F6){ref-type="fig"}). The best triple-combinations for separating MGUS and MM were sMICA-ADM-GDF15 (Figure [6A](#F6){ref-type="fig"}) as well as the combination of sMICA-ADM-REG4, sMICA-suPAR-REG4, sMICA-suPAR-sHGFR, ADM-suPAR-REG4, TRAP-REG4-sHGFR (data not shown). The triple-combinations increased the probability of correct classification of MGUS and MM; the classification error remained 0.062 (1 false/16). For discrimination of MGUS and MM, MM-ASCT from controls and MM from MM-ASCT, several combinations of only two analytes were sufficient to classify all samples correctly (with no misclassification error). For MGUS *vs* controls, the combinations were as follows: midkine-sTNFRSF4 (Figure [6B](#F6){ref-type="fig"}) or midkine-TGFB1, TGFB1-THPO, TGFB1-sHER4, TGFB1-IFNγ, and TGFB1-sIL17RB (data not shown). Best separation of MM and controls was observed for combinations PGF-sVEGFA (Figure [6C](#F6){ref-type="fig"}) and PGF-midkine. Regarding serum from MM and MM-ASCT, the best analyte pairs able to discriminate these groups were sBAFF-sAREG (Figure [6D](#F6){ref-type="fig"}) or the combination of sBAFF with sPECAM1 or sHGF (data not shown). For MM-ASCT *vs* controls, the combination of following analyte pairs resulted in 100% correct separation: sBAFF-GDF15 (Figure [6E](#F6){ref-type="fig"}) or sBAFF in combination with other analytes such as CSF1, sTGFA, TRAP, sTNFR2, sTNFRSF4 or HE4. Also, the combination of sTGFA with CSF1, sTNFR2 or Flt3L discriminated fully between MM-ASCT and healthy controls (data not shown).

![Extended Support Vector Machine (kSVM) analysis for identification of the minimum number and the best combination of proteins distinguishing MGUS, MM, and MM-ASCT\
The dots represent the individual patient data (combinations of two or three analytes). The contour plots show the probabilities (intervals: \> 90, 90-80, 80-70, 70-60, and 60-50%) for input data from individual patients to belong to the particular patient group. MGUS is colored yellow, MM red, MM-ASCT blue, and control subjects green. The more saturated color the higher probability of correct classification. **A.** MGUS *vs* MM, **B.** controls *vs* MGUS, **C.** controls *vs* MM **D.** MM *vs* MM-ASCT, **E.** controls *vs* MM-ASCT.](oncotarget-08-69408-g006){#F6}

DISCUSSION {#s3}
==========

In this study, we investigated the complexity of serum microenvironment in MGUS, MM and MM after ASCT using highly-sensitive PEA immunoassay. We hypothesized that serum of pre-cancer MGUS and MM differ by the presence of pro-tumorigenic factors. Indeed, we detected elevated levels of adrenomedullin (ADM), TRAP, GDF15, TGFB1, suPAR and other pro-tumorigenic proteins in serum of MM patients compared to MGUS. These proteins were already reported in MM but not investigated simultaneously. Pro-angiogenic factor ADM was identified as the most highly upregulated gene in hypoxia-dependent/independent fashion in MM cells, suggesting to be a major driving force for the angiogenic switch during MM evolution \[[@R11]\]. Highly upregulated TRAP is a marker of osteoclasts driving the bone resorption in MM \[[@R12]\]. The crucial role of TGFB1 in MM is supported by the observation that the inhibition of TGF-β signaling by TGF-β type I receptor kinase inhibitor causes a suppression of MM cell growth and an enhancement of bone formation \[[@R13]\]. Regarding GDF15 in MM, high serum levels were associated with poor prognosis \[[@R14], [@R15]\] and treatment response \[[@R16]\] and osteolysis \[[@R17]\]. GDF15 enhances the tumor-initiating and self-renewal potential of myeloma cells \[[@R18]\], contributes to drug resistance in both stroma-dependent/independent MM cells \[[@R14], [@R15]\], and promotes osteoclast differentiation while inhibits osteoblast differentiation \[[@R17]\]. Regarding suPAR, high suPAR expression in MM predicts progression, shorter survival and early extramedullary infiltration \[[@R19]\].

In order to detect the most promising circulating protein(s) distinguishing MGUS and MM, we analyzed co-occurrence of analytes in MGUS/MM classification models and identified sMICA as the most useful classifier. High serum levels of sMICA were already detected in MM as an adverse prognostic factor \[[@R20], [@R21]\], but not elevated in MGUS \[[@R20]\]. sMICA may originate from MICA-expressing MM cells, fibroblasts or other stromal cells upon stimulation \[[@R8], [@R22]\]. There is evidence that sMICA impairs the function of the NKG2D + T CD8+ and NK cells, contributing to myeloma cell immune escape \[[@R20]\]. Additionally, patients with MGUS, but not MM, generate high-titer anti-MICA antibodies that antagonize the suppressive effects of sMICA \[[@R20]\]. It has been therefore suggested that alterations in the NKG2D pathway by sMICA and anti-MICA antibodies are critically involved in the suppression of innate and adaptive immunity during the progression from MGUS to MM \[[@R20]\]. Importantly, some drugs may reconstitute the capabilities of sMICA-inhibited cytotoxicity of CD8+ and NK cells \[[@R23], [@R24]\], thus further highlights the potential of NKG2D + T CD8+ and NK cell-mediated immunotherapeutic interventions in MM \[[@R24], [@R25], [@R26]\].

Next, we investigated the minimum number and best combination of serum analytes able to discriminate between MGUS and MM. Advanced data mining methods revealed that the combination of sMICA and suPAR separates these groups with a classification error 0.062. The combination of triplets sMICA-ADM-GDF15 or sMICA-suPAR-REG4 increased the probability of correct classification of MGUS and MM with the same classification error (1/16) significantly. Although larger cohort studies are needed to confirm our results, our study nominated sMICA, ADM, GDF15, suPAR, and REG4 as key MM-associated serum proteins able to discriminate MGUS and MM.

Despite new therapies and ASCT increasing remission rates, nearly all MM patients ultimately succumb to disease relapse and progression. Because tumor microenvironment may contribute to these processes, we investigated for the first time serum pattern from paired samples from MM patients from the time of diagnosis and after ASCT (day 100). Interestingly, the post-transplant sera possessed high levels of soluble B-Cell Activating Factor (sBAFF), a survival factor for myeloma cells \[[@R9]\]. Enhanced serum levels of sBAFF, found produced by MM cells, immune and stromal cells \[[@R9], [@R27]\], correlated inversely with overall survival in MM and resistance to dexamethasone and lenalidomide \[[@R27], [@R28]\]. Since the elimination of sBAFF in an MM mouse model resulted in a decrease of tumor burden and protected against lytic bone disease \[[@R29]\], the sBAFF signaling represents a promising therapeutic target in MM \[[@R27]\], especially in the setting of post-transplant sBAFF elevation. After ASCT, the MM-associated proteins sMICA and ADM were downregulated but still elevated compared to healthy controls. On the other hand, serum levels of other pro-tumorigenic factors such as GDF15, CSF1, suPAR, and others did not change after ASCT comparing to paired MM sample at the diagnosis. Similar observation was reported in treated MM patients showing that cytokine pattern in those achieving remission is not restored to physiological levels \[[@R30]\], thus suggesting that once an individual has MM, the microenvironment is permanently altered and primed for a relapse. These results highlight the role of microenvironment for treatment success and may explain why MM remains an incurable disease.

We were also interested in MGUS associated serum pattern comparing to healthy controls. Our analysis revealed for the first time that MGUS is characteristic by low levels of TGFB1 and high levels of midkine, a heparin-binding growth factor involved in angiogenic and anti-apoptotic functions and tumor expansion in various cancers \[[@R31], [@R32]\]. Enhanced gene expression of midkine and other angiogenic factors were already reported in MM \[[@R33], [@R34]\] and also in this study we detected higher serum levels of midkine in MM *vs* MGUS. Importantly, lower gene expression of midkine and other angiogenic genes was detected in IMiD-responders compared to non-responders \[[@R34]\]. Elevation of midkine, produced by normal and malignant B-cells, tumor and stromal cells \[[@R35], [@R36]\], was also reported in other B-cell malignancies such as chronic lymphocytic leukemia and lymphomas \[[@R35]\]. Regarding TGFB1, low levels of TGFB1 were shown to control MM cell growth \[[@R13]\]. Our observations highlight the role of TGFB1 and midkine in the progression of MGUS to MM thus deserving further investigation.

We are aware that this study has several limitations. Because this study was focused on determination of serum protein fingerprinting, we did not analyze plasma bone marrow and did not investigate the functional effect of deregulated proteins. This should be performed in future studies.

In conclusion, we identified serum protein fingerprints associated with MGUS and MM as well changes ongoing in MM after ASCT. The knowledge of serum pattern may contribute to the identification of key myeloma cell survival factors, which may in turn influence treatment response and disease development.

MATERIALS AND METHODS {#s4}
=====================

Study population and materials {#s4_1}
------------------------------

The study cohort includes patients with MGUS (n=16) and MM (n=16); all patients were diagnosed according to the criteria of International Myeloma Working Group \[[@R37], [@R38]\]. Serum samples were taken at the time of diagnosis from previously untreated patients, aliquoted and stored at -80°C until analysis. In all enrolled MM patients, paired serum sample collected at day 100 after ASCT (MM-ASCT) was also analyzed. Patient characteristics are described in Table [2](#T2){ref-type="table"}. Serum samples from healthy control subjects (n=7, mean age 51 yrs; range 45-72 yrs, 4 males/3 females) were taken from members of medical staff; all completed a questionnaire regarding their health status. All patients provided written informed consent about the usage of peripheral blood for the purpose of this study. The study was approved by the ethics committee of University Hospital and Palacky University Olomouc.

###### Patient characteristics.

  Parameter                                                                    MGUS (n=16)   MM (n=16)
  ---------------------------------------------------------------------------- ------------- ------------------
  Age, years, median (min-max)                                                 59 (46-83)    57 (39-64)
  Gender, n, male/female                                                       8/8           5/11
  Paraprotein type, n (%)                                                                    
   IgG                                                                         11 (69)       7 (44)
   IgA                                                                         4 (25)        4 (25)
   IgD                                                                         1 (6)         0 (0)
   Light chain only                                                            0 (0)         5 (31)
  Bone lesions, n, yes/no                                                      0/16          12/4
  ASCT Induction regime, n (IMiD-based/bortezomib-based)\*                     NA            16 (8/8)
  Time difference from diagnosis to day 100 after ASCT, days, mean (min-max)   NA            314 (231-567)
  Response on day 100 after ASCT, CR/VGPR/PR, n (%)                            NA            11/4/1 (69/25/6)

\*1 patient received tandem ASCT

NA not applicable, CR complete remission, VGPR very good partial remission, PR partial remission

Proximity extension immunoassay {#s4_2}
-------------------------------

Serum profiles of ninety-two cancer-related proteins were assessed by the Proseek Multiplex Oncology I kit (Olink Bioscience, Uppsala, Sweden) according to the manufacturer's recommendation. Briefly, serum samples (1 µl) were incubated in the presence of 92 proximity antibody pairs tagged with DNA reporter molecules. Once the pair of antibodies bound to their corresponding antigens, the respective DNA tails formed by proximity extension an amplicon that was quantified by high-throughput real-time PCR (BioMark™ HD System, Fluidigm Corporation). The generated fluorescent signal directly correlates with protein abundance. Olink Wizard (Olink) was used for data normalization: the raw Cq-value (log2 scale) for each data point was normalized by subtracting the Cq-value for the extension control and compared to that of the corresponding background reaction resulting in a ddCq-value \[[@R39]\]. For further analysis, linearized values (2^ddCq^) were used. For panel description see [Supplementary Table S1](#SD2){ref-type="supplementary-material"}, for sensitivity and specificity parameters of PEA analysis see Assarsson et al. \[[@R39]\].

Pattern-recognition algorithms {#s4_3}
------------------------------

Binary classification by a stochastic nature-inspired symbolic regression method and evolutionary fuzzy-rules \[[@R40]\] was conducted in order to learn symbolic models for particular patient groups (MGUS, MM, MM-ASCT, healthy subjects) based on their serum protein pattern. For each tested patient group pair, the procedure was repeated more than 500 times to accommodate the stochastic nature of the algorithm and to obtain representative results. The most accurate classification models, separating all patients in the correct patient groups, were utilized for the identification of key molecules and those co-occurring in the classification rules characteristic for the particular patient group.

The proteins from the classification rules were further used to form a network model of patient classification with molecules as vertices and co-occurrences in successful classification models as edges. An algorithm based on analysis of the nearest neighbors between the studied molecules was applied to determine vertex and edge weights in the network model \[[@R41]\]. The size of the vertices (font-size) and connections among vertices show those proteins, which were used in classification rules of the particular patient group in the most accurate classification model.

Classification methods for separation of patient groups {#s4_4}
-------------------------------------------------------

To assess the minimum number and best combination of serum analytes distinguishing between the patient groups (MGUS *vs* MM, MM *vs* MM-ASCT), we applied several classification methods from the area of information retrieval such as Multilinear Discriminant Analysis, Naive Bayes classifiers, Random Forests, and kSVM to calculate the class probabilities for every input data (combinations of two or three analytes) and to determine the misclassification error \[[@R42], [@R43]\]. All methods were calculated using R statistical software with package Caret (<http://topepo.github.io/caret/index.html>).

Statistical analysis {#s4_5}
--------------------

Statistical analyses (Mann-Whitney-Wilcoxon and paired Wilcoxon tests) were performed using R statistical software package (<http://www.r-project.org/>). All data analyses were performed on linearized expression data (2^ddCq^) for each protein. A combination of box plots and swarm plots (a one-dimensional hybrid between scatter plot and strip chart) was employed to visualize the distribution of signals across subjects in particular subgroups. Radar charts were created for each pair of compared subgroups to visually assess the quantitative changes in levels of the most significant molecules, determined for each group pair by the Mann-Whitney-Wilcoxon test, and for paired samples (MM and MM-ASCT) by paired Wilcoxon test. *P*-value for each protein was adjusted for multiple comparisons using the False Discovery Rate (FDR) by the Benjamini-Hochberg procedure. A *P*-value \< .05 was considered as significant.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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ADM

:   Adrenomedullin

ASCT

:   Autologous stem cell transplantation

CA125

:   Cancer antigen 125

CA242

:   CA 242 tumor marker

CCL19

:   Chemokine (C-C motif) ligand 19

CCL21

:   Chemokine (C-C motif) ligand 21

CEA

:   Carcinoembryonic antigen

CR

:   Complete remission

CSF1

:   Colony stimulating factor 1

CXCL5

:   C-X-C motif chemokine 5

CXCL9

:   Chemokine (C-X-C motif) ligand 9

CXCL10

:   C-X-C motif chemokine 10

CXCL11

:   C-X-C motif chemokine 11

CXCL13

:   Chemokine (C-X-C motif) ligand 13

EPO

:   Erythopoietin

FABP4

:   Fatty acid binding protein 4

FDR

:   False Discovery Rate

Flt3L

:   FMS-like tyrosine kinase 3 ligand

GDF15

:   Growth differentiation factor 15

GM-CSF

:   Granulocyte-macrophage colony-stimulating factor

HE4

:   Human Epididymis Protein 4

Ig

:   Immunoglobulin

IL1RA

:   Interleukin-1 receptor antagonist

IL2

:   Interleukin 2

IL4

:   Interleukin 4

IL12

:   Interleukin 12

IMiD

:   Immunomodulatory drug

KLK6

:   Kallikrein-6

kSVM

:   Extended Support Vector Machine

MIA

:   Melanoma-derived growth regulatory protein

MGUS

:   Monoclonal gammopathy of undetermined significance

MM

:   Multiple myeloma

MYD88

:   Myeloid differentiation primary response 88

OPG

:   Osteoprotegerin

PEA

:   Proximity extension immunoassay

PGF

:   Placental growth factor

PR

:   Partial remission

PRL

:   Prolactin

REG4

:   Regenerating islet-derived protein 4

SMM

:   Smoldering multiple myeloma

TGFB1

:   Transforming growth factor beta 1

THPO

:   Thrombopoietin

TRAP

:   Tartrate-resistant acid phosphatase

sAREG

:   soluble Amphiregulin

sBAFF

:   soluble B-cell activating factor

sBTC

:   soluble Betacellulin

sCAIX

:   soluble Carbonic anhydrase 9

sCD30L

:   soluble CD30 ligand

sE selectin

:   soluble E-selectin

sEGFR

:   soluble Epidermal growth factor receptor

sEMMPRIN

:   soluble Extracellular matrix metalloproteinase inducer

sEpCAM

:   soluble Epithelial cell adhesion molecule

sEpiregulin

:   soluble Epiregulin

sER

:   soluble Estrogen receptor

sFasL

:   soluble Fas ligand

sFOLR1

:   soluble Folate receptor alpha

sHBEGF

:   soluble Heparin-binding EGF-like growth factor

sHER3

:   soluble Receptor tyrosine-protein kinase erbB-3

sHER4

:   soluble Receptor tyrosine-protein kinase erbB-4

sHGF

:   soluble Hepatocyte growth factor/scatter factor

sHGFR

:   soluble Hepatocyte growth factor receptor

sIL2RA

:   soluble Interleukin-2 receptor alpha chain

sIL17RB

:   soluble Interleukin-17 receptor B

sMICA

:   soluble MHC class I polypeptide-related sequence A

sPDGFB

:   soluble Platelet-derived growth factor subunit B

sPECAM1

:   soluble Platelet endothelial cell adhesion molecule

sSCF

:   soluble Stem cell factor

sTF

:   soluble Tissue Factor

sTGFA

:   soluble Transforming growth factor alpha

sTIE2

:   soluble Receptor tyrosine kinase Tie2

sTNFR1

:   soluble Tumor necrosis factor receptor 1

sTNFR2

:   soluble Tumor necrosis factor receptor 2

sTNFRSF4

:   soluble Tumor necrosis factor receptor superfamily member 4

suPAR

:   soluble Urokinase plasminogen activator receptore

sVEGFA

:   soluble Vascular endothelial growth factor A

VGPR

:   Very good partial remission
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